Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evan Y Yu

Showing results (51-60 of 234) with videos related to

Pageof 24
Sort By:
The Journal of Urology|May 16, 2012
Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancerEvan Y Yu, Kurt Miller, Joel Nelson, et al.
Medical Oncology (Northwood, London, England)|June 15, 2016
Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancerMichael T Schweizer, Roman Gulati, Elahe A Mostaghel, et al.
The Prostate|July 11, 2018
Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survivalDaniel M Lim, Roman Gulati, Serge Aleshin-Guendel, et al.
American Journal of Clinical and Experimental Urology|November 9, 2023
Determining clinical perspectives and strategies for improving enrollment of minoritized communities in prostate cancer clinical trialsLauren Brady, Jenney R Lee, Evan Y Yu, et al.
BJU International|January 23, 2019
Chemotherapy regimen is associated with venous thromboembolism risk in patients with urothelial tract cancerJorge D Ramos, Sarah K Holt, George R Schade, et al.
Investigational New Drugs|December 19, 2017
A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancerEvan Y Yu, Susan L Ellard, Sebastien J Hotte, et al.
Clinical Genitourinary Cancer|April 24, 2020
Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men With Castration-Resistant Prostate CancerEvan Y Yu, Michael L Hancock, William Aronson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2010
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivationEvan Y Yu, Roman Gulati, Donatello Telesca, et al.
Plos One|May 27, 2020
Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapiesLaura S Graham, Bruce Montgomery, Heather H Cheng, et al.
The Prostate|February 13, 2023
Clinical, pathologic, and molecular features of amphicrine prostate cancerLaura S Graham, Michael C Haffner, Erolcan Sayar, et al.
Pageof 24

Showing results (51-60 of 234) with videos related to

Sort By:
Pageof 24
The Journal of Urology|May 16, 2012
Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancerEvan Y Yu, Kurt Miller, Joel Nelson, et al.
Medical Oncology (Northwood, London, England)|June 15, 2016
Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancerMichael T Schweizer, Roman Gulati, Elahe A Mostaghel, et al.
The Prostate|July 11, 2018
Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survivalDaniel M Lim, Roman Gulati, Serge Aleshin-Guendel, et al.
American Journal of Clinical and Experimental Urology|November 9, 2023
Determining clinical perspectives and strategies for improving enrollment of minoritized communities in prostate cancer clinical trialsLauren Brady, Jenney R Lee, Evan Y Yu, et al.
BJU International|January 23, 2019
Chemotherapy regimen is associated with venous thromboembolism risk in patients with urothelial tract cancerJorge D Ramos, Sarah K Holt, George R Schade, et al.
Investigational New Drugs|December 19, 2017
A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancerEvan Y Yu, Susan L Ellard, Sebastien J Hotte, et al.
Clinical Genitourinary Cancer|April 24, 2020
Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men With Castration-Resistant Prostate CancerEvan Y Yu, Michael L Hancock, William Aronson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2010
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivationEvan Y Yu, Roman Gulati, Donatello Telesca, et al.
Plos One|May 27, 2020
Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapiesLaura S Graham, Bruce Montgomery, Heather H Cheng, et al.
The Prostate|February 13, 2023
Clinical, pathologic, and molecular features of amphicrine prostate cancerLaura S Graham, Michael C Haffner, Erolcan Sayar, et al.
Pageof 24